Cellceutix Anti-Cancer Drug Kevetrin Completes Dosing Cycle,

Cellceutix Anti-Cancer Drug Kevetrin Completes Dosing Cycle, Ready
for Next Cohort 
BEVERLY, MA -- (Marketwire) -- 12/03/12 --  Cellceutix Corporation
(OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical
company focused on discovering small molecule drugs to treat unmet
medical conditions, including drug-resistant cancers and autoimmune
diseases, is pleased to report that clinical trials for Kevetrin(TM),
the Company's flagship anti-cancer drug, are progressing smoothly. In
the clinical trials, being conducted at Harvard University's
Dana-Farber Cancer Institute and partner Beth Israel Deaconess
Medical Center, the cohort which began treatment with Kevetrin early
in November has completed the initial cycle. 
To date, the group of subjects has been reported to be within normal
parameters of the clinical protocol. A total of 84 blood samples from
the patients have just been sent to the laboratory for
pharmacokinetics analysis. 
As per the clinical protocol, the Safety Committee will now meet to
approve continuation of dose administration for the benefit of that
group of patients and to approve increasing the dose for the next
group of patients, which the Company expects to begin in
"The clinical trials are progressing extremely well and 
right on
schedule," commented Dr. Krishna Menon, Chief Scientific Officer at
Cellceutix. "As we await the lab reports, it's very encouraging that
we have not seen any of the toxic side effects that are commonly
associated with chemotherapy at this point. Many new drugs
demonstrate toxicity immediately, so I interpret the information on
Kevetrin(TM) with a great deal of optimism. We are excited for the
upcoming weeks when the next cohort, in which dosing levels will be
doubled, may provide us even greater insight on what we believe is
the most exciting oncologic drug in development today." 
Regarding Prurisol(TM), the Company's drug in development as a new
therapy for psoriasis, Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's")
has advised the Company that scale-up manufacturing is underway.
During the pilot developmental studies, Dr. Reddy's was able to
improve the yield and purity and reduced the synthetic steps
required. This will save Cellceutix valuable time and money in the
manufacturing of Prurisol for the planned Phase 2 / 3 clinical
About Kevetrin(TM) 
As a completely new class of chemistry in medicine, Kevetrin(TM) has
significant potential to be a major breakthrough in the treatment of
solid tumors. Mechanism of action studies showed Kevetrin's unique
ability to affect both wild and mutant types of p53 (often referred
to as the "Guardian Angel Gene" or the "Guardian Angel of the Human
Genome") and that Kevetrin strongly induced apoptosis (cell death),
characterized by activation of Caspase 3 and cleavage of PARP.
Activation of p53 also induced apoptosis by inducing the expression
of p53 target gene PUMA. p53 is an important tumor suppressor that
acts to restrict proliferation by inducing cell cycle checkpoints,
apoptosis, or cellular senescence. 
In more than 50 percent of all human carcinomas, p53 is limited in
its anti-tumor activities by mutations in the protein itself.
Currently, there are greater than 10 million people with tumors that
contain inactivated p53, while a similar number have tumors in which
the p53 pathway is partially abrogated by inactivation of other
signaling components. This has left cancer researchers with the grand
challenge of searching for therapies that could restore the protein's
protective function, which Kevetrin appears to be doing the majority
of the time.
 The clinical trial titled, "A Phase 1, Open-Label,
Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of
Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in
Patients With Advanced Solid Tumors," is available at:
About Cellceutix 
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly
traded company under the symbol "CTIX". It is an emerging
bio-pharmaceutical company focused on the development of its pipeline
of compounds targeting areas of unmet medical need. Our flagship
compound, Kevetrin(TM), is an anti-cancer drug which has demonstrated
the ability in pre-clinical studies to regulate the p53 pathway and
attack cancers which have proven resistant to today's cancer
therapies (drug-resistant cancers). Cellceutix also owns the rights
to seven other drug compounds, including KM-133, which is in
development for psoriasis, and KM-391 for the treatment of the core
symptoms of autism. More information is available on the Cellceutix
web site at www.cellceutix.com. 
Safe Harbor Forward-Looking Statements 
To the extent that statements in this press release are not strictly
historical, including statements as to revenue projections, business
strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements,
the success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made. Factors that
may impact Cellceutix's success are more ful
ly disclosed in
Cellceutix's most recent public filings with the U.S. Securities and
Exchange Commission. 
Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
Press spacebar to pause and continue. Press esc to stop.